DICE Therapeutics is discovering novel small molecules that can be used to treat various inflammatory diseases. Many current medicines to treat inflammatory diseases are not suited for chronic treatment as they would require regular patient monitoring and administration through injections or intravenous infusions. DICE is using their DELSCAPE platform to identify oral small molecules that modulate the binding of an inflammatory cytokine to its receptor as effectively as systemic biologics. Their growing pipeline of oral therapeutic candidates includes their lead program, DC-806 , that targets the IL-17 cytokine for psoriasis and other IL-17 mediated diseases.

DICE Therapeutics

Founded: 2013
Location: South SF, CA
Employee range: 50 - 200
Clinical stage: Clin1
Therapy area: Psoriasis, immune-mediated conditions
Drug types: IMM, DRM, GI, ONC
Lead product: DC-806
Funding: $345M stock Oct 2022; $204M IPO Sep 2021; $60M C-1 Aug 2021; $80M C Jan 2021

Drug notes:

About:

Jobs: